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Identification of driver mutations in human diseases
is often limited by cohort size and availability of
appropriate statistical models. We propose a frame-
work for the systematic discovery of genetic alter-
ations that are causal determinants of disease, by
prioritizing genes upstream of functional disease
drivers, within regulatory networks inferred de novo
from experimental data. We tested this framework
by identifying the genetic determinants of themesen-
chymal subtype of glioblastoma. Our analysis uncov-
ered KLHL9 deletions as upstream activators of
two previously established master regulators of the
subtype, C/EBPb and C/EBPd. Rescue of KLHL9
expression induced proteasomal degradation of C/
EBP proteins, abrogated the mesenchymal signa-
ture, and reduced tumor viability in vitro and in vivo.
Deletions of KLHL9 were confirmed in > 50% of
mesenchymal cases in an independent cohort, thus
representing the most frequent genetic determinant
of the subtype. The method generalized to study
other human diseases, including breast cancer and
Alzheimer’s disease.
INTRODUCTION
Identification of somatic mutations and germline variants that
are determinants of cancer and other complex human dis-
eases/traits (drivermutations) ismostly performed on a statistical
basis, using models of genomic evolution (Frattini et al., 2013) or
mutational bias (Lawrence et al., 2013), among others, to in-402 Cell 159, 402–414, October 9, 2014 ª2014 Elsevier Inc.crease the significance of individual events. Achieving appro-
priate statistical power, however, requires large effect sizes or
large cohorts due to multiple hypothesis-testing correction (Cal-
ifano et al., 2012). In addition, these approaches are not designed
to provide mechanistic insight. As a result, many disease-risk
determinants, such as apolipoprotein E, were discovered long
before they were mechanistically elucidated (Liu et al., 2013).
Network-based analyses have recently emerged as a highly
effective framework for the discovery of master regulator (MR)
genes that are functional disease drivers (Aytes et al., 2014;
Carro et al., 2010; Lefebvre et al., 2010; Piovan et al., 2013;
Sumazin et al., 2011; Zhao et al., 2009). Here, we introduce
DIGGIT (driver-gene inference by genetical-genomics and
information theory), an algorithm to identify genetic determinants
of disease by systematically exploring regulatory/signaling net-
works upstream of MR genes. This collapses the number of test-
able hypotheses and provides regulatory clues to help elucidate
associated mechanisms.
We first apply DIGGIT to identify causal genetic determinants
of the mesenchymal subtype of GBM (MES-GBM), which remain
poorly characterized despite extensive efforts (Brennan et al.,
2013; Verhaak et al., 2010). We then demonstrate its generaliz-
ability to other diseases for which matched expression and
mutational data are available.
Astrocytoma grade IV or glioblastoma (GBM) is the most com-
mon human brain malignancy and is virtually incurable, with
average survival of 12–18 months post-diagnosis (Ohgaki and
Kleihues, 2005). Gene-expression profile analysis revealed three
subtypes associated with expression of mesenchymal, prolifer-
ative, and proneural (PN) genes, respectively (Phillips et al.,
2006). Among these, mesenchymal tumors (MES-GBM) present
with the worst prognosis, as confirmed by other studies (Carro
et al., 2010; Sun et al., 2006; Cancer Genome Atlas
Research Network, 2008). Integrative analysis of expression
and mutational data (Cancer Genome Atlas Research Network,
2008) produced a more complex stratification into PN, MES,
neural, and classic subtypes, as well as into an epigenetically
distinct subtype (G-CIMP) with the best prognosis (Verhaak
et al., 2010). Whereas non-G-CIMP PN tumors were associated
with the worst prognosis by Brennan et al. (2013), MES-GBM tu-
mors, based on the original classification, present virtually indis-
tinguishable prognosis and are7-fold more frequent (Figure S1
available online). Thus the original MES-GBM and the newer
Non-G-CIMP PN signatures are both objective, equivalent
markers of poor prognosis.
Among the genetic alterations reported by the TCGA
Consortium (Cancer Genome Atlas Research Network, 2008),
only NF1 mutations/deletions were associated with MES-GBM
tumors (25% of samples) (Verhaak et al., 2010), although addi-
tional rare mutations and fusion events were recently reported
(Danussi et al., 2013; Frattini et al., 2013). Thus, despite multiple
studies, the genetic determinants of MES-GBM are still largely
elusive and represent an ideal target for the new algorithm.
In Carro et al. (2010), we reported that aberrant coactivation of
the transcription factors (TFs) C/EBPb, C/EBPd, and STAT3 is
necessary and sufficient to induce mesenchymal reprogram-
ming in GBM, suggesting that this TF module represents an obli-
gate pathway or regulatory bottleneck between driver alterations
and aberrant mesenchymal program activity. We thus hypothe-
size that the genetic drivers ofMES-GBMare either among these
genes or in their upstream pathways. Use of DIGGIT to test the
hypothesis elucidated two high-frequency alterations: focal
amplification of C/EBPd and homozygous deletion of KLHL9, a
Cullin E3 ligase adaptor (Sumara et al., 2007).
To assess the algorithm’s generalizability to other diseases
and germline variants, we also applied it to breast cancer
(BRCA) and Alzheimer’s disease (AD). This identified driver alter-
ations and variants missed by genome-wide association studies
(GWASs) but validated by independent candidate-gene studies,
as well as high-probability, yet unreported events.
RESULTS
Given a set of functional disease drivers, e.g., inferred by the MR
inference algorithm (MARINa) (Aytes et al., 2014; Carro et al.,
2010), DIGGIT evaluates candidate alterations in these genes
and in their upstream regulators (see Figure 1A for a flowchart).
This is accomplished by a five-step process (Figures 1B–1F),
requiring a large set (nR200) of gene-expression profiles (hence-
forth GEPD) to assemble and analyze regulatory networks and a
large set (n R100) of sample-matched genetic-variant profiles
(henceforth GVPD). We first discuss application of this pipeline
to identify copy-number variants (CNVs) that are causal determi-
nants of the MES-GBM subtype. We then perform additional an-
alyses to show that DIGGIT generalizes to the study of germline
variants, as well as of other diseases, including BRCA and AD.
Step 1: MR Analysis
This step requires a context-specific regulatory network repre-
senting TF/ target interactions (henceforth, interactome) and
a gene-expression signature of interest (i.e., a p value-ranked
list of differentially expressed genes) (input). These are analyzedby MARINa to produce a p value-ranked list of candidate
MRs (output). Given a GEPD data set, networks can be in-
ferred using available reverse-engineering algorithms, such as
ARACNe (Basso et al., 2005). Specifically, MARINa analysis
of an ARACNe-inferred GBM network, using a MES-GBM
signature, identified six MR genes (MES-MRs), including
C/EBPb, C/EBPd, STAT3, BHLHB2, RUNX1, and FOSL2, with
C/EBPb/C/EBPd and STAT3 as synergistic MRs (Carro et al.,
2010). See Figure 1B.
Step 2: F-CNVG Analysis
Functional alterations must induce aberrant activity of their gene
products (see Figure 1C). Among copy-number alterations
(CNVGs), we thus select those whose ploidy is informative of
gene expression as candidate functional CNVs (F-CNVGs) (Tam-
borero et al., 2013) (Figure S1). This is assessed based on (1)
mutual information (MI) between copy number and expression
or (2) differential expression in wild-type (WT) versus amplified/
deleted samples (see Extended Experimental Procedures). Ana-
lyses are performed on the GEPD and sample-matched GVPD
profiles (input), independent of subtype classification, to pro-
duce a p value-ranked list of candidate F-CNVGs (output).
Analysis of 229 profile-matched GBM samples in TCGA identi-
fied 1,486 candidate F-CNVGs (p%0:05, Bonferroni corrected).
The MI test proved highly sensitive, accounting for 90% of in-
ferred F-CNVGs (Tables S1–S5) (both KLHL9 and C/EBPd were
positivebyMIanalysis),with the t test accounting for anadditional
10% of low-frequency F-CNVGs, with lowMI analysis sensitivity.
Most CNVGs (94%) were thus discarded as not informative of
gene expression (see Figure S1), suggesting no functional
contribution.Conversely, inferredF-CNVGs includedmostgenes
previously reported as GBM drivers (14/18 > 88%) (Cancer
Genome Atlas Research Network, 2008), including EGFR,
CDK4, PDGFRA, MDM2, MDM4, MET, AKT3, MYCN, PIK3CA,
CDKN2A, CDKN2C, RB1, PTEN, and NF1 (p = 1.2 3 1010)
(Tables S1–S5). Analysis of remaining driver genes (CCND2,
CDK6, CDKN2B, PARK2) revealed that they were missed due
to either low event frequency (CDK6 < 1.3%, CCND2 < 2.2%,
PARK2 < 5.2%) or below-detection gene-expression levels
(CDKN2B).
Among the MES-MRs, only C/EBPd was inferred as a focally
amplified F-CNVG (22% of samples), suggesting that aberrant
activity of other MES-MRs may be mediated by alterations in
their upstream regulators.
Step 3: MINDy Analysis
Next, we used the MINDy algorithm to interrogate pathways
upstream of MR genes (Wang et al., 2009). MINDy analyzes a
large GEPD, the candidate MR list (step 1), and the F-CNVG
list (step 2) (input) to identify F-CNVGs that are candidate post-
translational modulators of MR activity (independent of subtype
classification), by conditional MI analysis (Wang et al., 2009;
Zhao et al., 2009; see Extended Experimental Procedures).
This generates a p value-ranked list of candidate F-CNVGs in
pathways upstream of MR genes (output). This step dramatically
reduced the 1,486 F-CNVGs from step 1 to only 92 statistically
significant candidate MES-MR modulators (see Table S3 and
Figure 1D).Cell 159, 402–414, October 9, 2014 ª2014 Elsevier Inc. 403
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Step 4: aQTL Analysis
F-CNVGs are then analyzed to identify those whose alteration is
predictive of MR activity, similar to expression quantitative trait
loci (eQTL) discovery (Yang et al., 2009). Activity quantitative trait
loci (aQTL) are inferred based on the statistical significance of
the MI between copy number and MR activity. For each candi-
date F-CNVG, this is computed using the MR list (step 1), the
F-CNVG list (step 2), the GEPD data set, and the interactome
(input) to generate a p value-ranked list of candidate F-CNVG-
aQTL (output). Differential MR activity is inferred from their
differential target expression, using a single-sample version of
MARINa (see Experimental Procedures). This is critical, as MRs
are frequently differentially active but not differentially expressed
(Aytes et al., 2014; Carro et al., 2010). Overall, 125 out of 1,486
F-CNVGs from step 2 were inferred as aQTLs, including both
C/EBPd and KLHL9 (Figures 1E, 2A, and S2; Table S3).
Step 5: Conditional Association Analysis
MINDy and aQTL analyses are probabilistically integrated, using
Fisher’s method, to prioritize F-CNVGs for the final step (see Fig-
ure 1F). As shown by the 2-fold reduction in candidate F-CNVGs
(Table S3), these analyses provide largely statistically indepen-
dent evidence.
CNVs can span multiple genes, resulting in statistical depen-
dencies equivalent to linkage disequilibrium (LD) in classical
genetics. Indeed F-CNVG clustering by sample cosegregation
identified 34 clusters (Figure 2B), largely reflecting chromosomal
proximity. Conditional analysis helps assesswhether association
of a F-CNVG (F-CNVi) with the phenotype may be an artifact re-
sulting from its physical proximity to a bona fide driver F-CNVG
(F-CNVj), in which case conditional association of F-CNVi with
the phenotype (i.e., using only F-CNVj
WT samples) should not
be statistically significant, thus removing such artifacts. This
step requires MINDy/aQTL-prioritized F-CNVGs (steps 3/4), a
phenotypic classifier, and the GEPD data set (input) to produce
a final p value-ranked list of candidate driver F-CNVGs (output).Figure 1. The General Workflow of DIGGIT
(A) Overall flowchart of the DIGGIT pipeline. Green, red, and blue arrows indicate
(B) Step 1: Identification of candidate MRs as TFs that activate and repress over-a
To avoid clutter, only one MR (blue circle) is represented in the panel. Grey circles
phenotype, whereas those within the two diagonal lines (funnel) represent altera
causal driver alteration.
(C) Step 2: F-CNVGs are determined by association analysis of copy number and
of genes whose expression is not affected by ploidy. The insert shows two exam
and not selected as a candidate F-CNVG and (2) an example with highly signific
(D) Step 3: MINDy analysis identifies F-CNVGs that are candidate modulators of M
a candidate modulator gene and T is an ARACNe-inferred MR-target gene. Blue a
Green arrows represent one specificM/MR/ T triplet tested byMINDy, as an
fact that a protein is an upstream modulator of MR activity.
(E) Step 4: aQTL analysis identifies F-CNVGs (shown as white circles), whose alt
expression and shown by the blue arrows. The insert shows details of this an
overexpressd (red) to the most underexpressed (blue), when comparing samples
(thin black lines). If MR targets significantly cosegregate with the differential expre
red and blue bars, are over- and underexpressed, respectively, as shown), then
(F) Step 5: Finally, conditional association analysis identifies F-CNVGs that abroga
samples harboring their alterations are removed from the analysis. Each cell show
the phenotype of interest (as a heatmap), when considering only samples that ha
G3, no other gene is significantly associated with the subtype, whereas G3 is still
This suggests that G3 is a bona fide driver gene.For MES-GBM, the 41 F-CNVGs inferred as significant from
integrative MINDy/aQTL analysis (Table S3) cosegregated into
5 distinct clusters: a 7-gene cluster (chr5, 7, 8, and 19) including
the C/EBPd locus; a 15-gene cluster (chr9) including the KLHL9/
CDKN2A locus; an 11-gene cluster (chr7) including the EGFR
locus; a 5-gene cluster (chr19); and a 3-gene cluster (chr10)
(see Figures 2C and S3). The first cluster presented with a highly
unlikely cosegregation pattern distributed over four chromo-
somes (p = 9.5 3 1012). In addition, C/EBPd amplifications on
chr8 also cosegregated with NF1 point mutations, whose asso-
ciation with the MES-GBM subtype was previously reported
(Verhaak et al., 2010). Given that MINDy infers NF1 as a STAT3
but not a C/EBPb/d modulator and these proteins cooperate
synergistically to induce MES reprogramming, this suggests
a possible cooperative role of C/EBPd and NF1 mutations.
The 41 F-CNVGs were tested for conditional association to
the MES subtype (Figure 2C). Only C/EBPd and KLHL9 abro-
gated association of all other F-CNVGs, while remaining sig-
nificant when conditioning on other F-CNVGs (see Figures 2C
and S3).
Conditional analysis discarded CDKN2A, a well-established
tumor suppressor located proximally to KLHL9, as candidate
causal drivers of MES-GBM. Indeed, 85 samples with homo-
zygous CDKN2A deletions but an intact KLHL9 locus
(iCDKN2A//KLHL9WT) were not associated with MES-GBM.
Conversely, 38 CDKN2A//KLHL9/ samples (excluding
C/EBPd amplifications to avoid confounding factors) were highly
associated with MES-GBM (p = 2.1 3 105), when compared to
CDKN2A//KLHL9WT samples.
Using a stringent call threshold, C/EBPdAmp and KLHL9/
events account for 48% of TCGA MES-GBM samples (Fig-
ure 2D), with independent deletions/mutations of NF1 cover-
ing an additional 8%, suggesting that these may constitute
the most common subtype drivers. Table S3 summarizes the
reduction in candidate F-CNVGs resulting from each step of the
analysis.use of MRs, F-CNVGs, and MINDy/aQTL analysis results, respectively.
nd underexpressed genes, respectively, as inferred by the MARINa algorithm.
represent the repertoire of genetic alterations that may be associated with the
tions in pathways upstream of the MR. The red circle represents a bona fide
gene expression (see Experimental Procedures), thus removing a large number
ples: (1) an example of no dependency between copy number and expression
ant dependency and thus selected as a candidate F-CNVG.
R activity (shown as yellow circles) by computing the cMI I[MR;TjM], whereM is
rrows represent physical signal-transduction interactions upstream of the MR.
illustrative example. Note thatMINDy does not infer the blue arrows but only the
erations cosegregate with aberrant MR activity, as computed from MR-target
alysis. The vertical gradient rectangle shows all genes sorted from the most
with copy-number alterations in a gene (Gene X) (thick red lines) to WT samples
ssion signature (i.e., if positively regulated and repressedMR targets, shown as
Gene X alterations are likely to affect MR-activity.
te all other associations with the phenotype (e.g., theMES-GBMsubtype) when
s the statistical significance of the association between the i-th gene (rows) and
ve no alterations in the j-th gene (columns). For instance, when conditioning on
significantly associated with the subtype when conditioning on G1, G2, or G4.
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Figure 2. DIGGIT Integrative Analysis Infers
Candidate MES-GBM Driver Mutations
(A) DIGGIT analysis of pathways upstream of
MES-GBM MRs identifies CEBPd amplification
and KLHL9 deletions as candidate genetic de-
terminants of the GBM-MES subtype. p values
shown represent the integrated p value of the aQTL
and MINDy steps, as defined in Figure 1.
(B) Comutated F-CNVGs are shown as a network,
with distance between connected nodes inversely
proportional to the statistical significance of their
cosegregation, as assessed by Fisher’s exact test
(FET). Only statistically significant pairs are shown
(p = 0.05, corrected), with amplifications and
deletions represented as blue and red nodes,
respectively. Chromosome location is reported for
the larger clusters, and nodes representingC/EBPd
and KLHL9 are highlighted.
(C) Conditional association analysis for the two
main cosegregating mutation clusters identified by
DIGGIT. Color scale in thematrix cell (i,j) represents
the strength of association (log10(p)) between
the i-th F-CNVG (row) and the MES subtype, con-
ditional to removing samples with alterations in the
j-th F-CNVG (column). See Figure S3.
(D) Effect size of DIGGIT-inferred genetic de-
terminants of the MES-GBM subtype. ‘‘Classical’’
GBM oncogenes are shown only as a reference, for
comparison purposes. Marks indicate amplification
(+)deletion () anddiploid (WT) status for eachgene.Association of KLHL9 Deletions Is Confirmed in an
Independent Cohort
Because C/EBPd is a validated MES-MR (Carro et al., 2010),
we focused on the functional significance of homozygous
KLHL9 deletions. First, we tested whether their association
with poor prognosis could be validated in an independent
cohort. We analyzed 63 FFPEs, representing 40 poor-prog-
nosis (survival < 35 weeks) and 23 good-prognosis (survival
> 130 weeks) GBM samples. Quantitative genomic PCR
revealed higher frequency of homozygous KLHL9 deletions
in poor-prognosis (21/40) versus good-prognosis samples
(4/23) (p = 0.006, by FET; Figures 3A and 3B). This suggests
an even higher frequency (>50%) than in TCGA samples
(38%). IHC staining of 10 KLHL9/ and 10 KLHL9WT
confirmed association with aberrant C/EBPb and C/EBPd
protein expression in vivo (odds ratio 12.25, p = 0.028) (Fig-
ure 3C). This confirms KLHL9/ events as poor-prognosis
biomarkers and their association with aberrant MES-MR activ-
ity in vivo. No KLHL9 missense or nonsense mutations were
detected.
C/EBPd and KLHL9 Alterations Are Predictive of Poor
Prognosis in Multiple Tumors
Mesenchymal reprogramming is generally associated with poor
outcome in cancer (Thiery, 2002). We thus assessed whether
C/EBPdAmp and KLHL9/ events may be predictive of poor406 Cell 159, 402–414, October 9, 2014 ª2014 Elsevier Inc.prognosis in GBM and other tumors, inde-
pendent of potentially controversial sub-
type classification.In GBM, Kaplan-Meier analysis revealed significantly worse
prognosis for patients harboring C/EBPdAmp and KLHL9/
alterations, compared to either good-prognosis (i.e., nonmesen-
chymal) (Figure 3D, p = 3.5 3 104) or C/EBPdWT/KLHL9WT
patients (Figure 3D, p = 0.03). None of the patients with these
alterations survived longer than 36 weeks post-diagnosis (see
vertical bars in Figure 3D), and patients harboring both events
had the worst overall prognosis, suggesting a cooperative effect.
Thus, C/EBPdAmp and KLHL9/ represent genetic biomarkers
of poor prognosis, independent of subtype classification.
Kaplan-Meier analysis of COSMIC and TCGA cohorts re-
vealed that KLHL9 homozygous deletions and missense/
nonsense mutations are associated with the worst prognosis
also in lung (LuAd) and ovarian (OvCa) adenocarcinomas (Fig-
ures 3E and 3F) (p = 1.83 103 and p = 0.04, respectively), inde-
pendent of CDKN2A status. In OvCa, most KLHL9/ samples
had no CDKN2A loss. Gene set enrichment analysis (GSEA)
(Subramanian et al., 2005) confirmed aberrant C/EBPb and/or
C/EBPd activity in KLHL9/ samples, suggesting a possible
pan-cancer role of KLHL9 deletions via aberrant C/EBP activity
(Figure S4).
Ectopic KLHL9 Expression in GBM Cells Abrogates
C/EBPb and C/EBPd Abundance
To mechanistically elucidate KLHL9-mediated regulation of es-
tablished MES-MRs (C/EBPb, C/EBPd, and STAT3), we rescued
Figure 3. KLHL9 Deletions Are Associated
with Aberrant C/EBPb and C/EBPd Levels
and Poorest Prognosis in an Independent
GBM Cohort
(A) Genomic qPCR analysis of primary tumors from
an independent 63 GBM patient cohort, shown as
CT values. Values higher than the red horizontal
line (max CT threshold) represent statistically sig-
nificant homozygous KLHL9 deletions (KLHL9/)
(p% 0.05). Values are reported as mean ± SEM.
(B) Contingency table generated from qPCR re-
sults in (A), showing the statistical significance of
the association between KLHL9/ alterations and
poor prognosis, as assessed by FET analysis.
(C) IHC staining for C/EBPb and C/EBPd in primary
samples shows stronger immunoreactivity in
KHLH9/ samples compared to KLHL9WT con-
trols. Association between KLHL9/ alterations
and aberrant expression of C/EBP proteins is
summarized by odds ratio (OR) and p value (FET);
representative IHC slides are shown.
(D) Kaplan-Meier analysis of GBM samples in
TCGA. Patients with KLHL9/ and C/EBPdAmp
events are shown as a red curve; proneural sub-
type patients are shown as a black curve; finally,
KLHL9WT/CEBPdWT samples are shown as a blue
curve. Kaplan-Meier p values are shown, including
p1 (red versus blue) and p2 (red versus black).
Survival for patients with each specific genotype is
shown as vertical bars below the plot.
(E and F) Kaplan-Meier analysis of the association
between KLHL9/ alterations and poor prognosis
in lung and serous ovarian adenocarcinoma,
respectively. Analysis of inferred differential ac-
tivity of C/EBPb and C/EBPd in KLHL9/ samples
is shown in Figure S4.KLHL9 expression in homozygously deleted cells. Genomic
analysis of a GBM cell line panel identified SF210 and SF763
cells as KLHL9/;CDKN2A/;C/EBPWT.
Following inducible lentivirus-mediated rescue of KLHL9
expression in SF210 cells, two independent clones (KLHL9-4
and KLHL9-7) showed stable KLHL9 levels by western blot, up
to 96 hr post-induction (Figures 4A and 4B). Although C/EBPb
andC/EBPd expressionwas not significantly affected (Figure 4C,
inset), RNA-seq profiling revealed significant differential expres-
sion of ARACNe-inferred C/EBPb and C/EBPd targets by GSEA
(p = 0.004), compared to controls (Figure 4A), with significant
downregulation of established MES markers: CHI3L1/YKL40,
LIF, FOSL2, ACTA2, and FN1. Consistently, we observed signif-
icant reduction in C/EBPd andmoremodest decrease in C/EBPb
protein levels. Levels of phospho-STAT3, representing the
transcriptionally active isoform, were also reduced (Figure S5).
These results were recapitulated in SF763 cells, with marked
reduction of C/EBPd levels and more modest reduction of the
C/EBPb-LIP isoform in cells expressing KLHL9 relative to con-
trols expressing RFP. Conversely, exogenous expression of
P16/INK4A (CDKN2A) in SF210 had no effect on either C/EBPb
or C/EBPd protein expression or on the MES signature genes
(Figure S5).These results show that rescue of KLHL9 expression col-
lapses the MES-GBM signature by downregulating C/EBPb
and C/EBPd at the protein level. This effect may be mediated
by ubiquitin-dependent proteasomal degradation, as previously
reported for the AuroraB kinase (Figure 4B).
Proteasomal Degradation of C/EBPb and C/EBPd
Depends on KLHL9-Mediated Polyubiquitylation
Given KLHL9’s putative function as an adaptor ofCul3-based E3
ubiquitin ligase (Sumara et al., 2007), we tested its role in
mediating polyubiquitylation-dependent proteasomal degrada-
tion of C/EBPb and C/EBPd. Direct physical interaction between
KLHL9 and both C/EBPb andC/EBPd proteins was confirmed by
coimmunoprecipitation assays (Figure 5A). We then measured
degradation and relative half-life of C/EBPb and C/EBPd
following rescue of KLHL9 expression in SF210 (Figure 5B). C/
EBPb and C/EBPd levels were significantly reduced at 4 hr
following ectopic KLHL9 expression and cycloheximide-medi-
ated inhibition of protein translation (Figure 5B). Finally, MG-
132-mediated proteasome inhibition abrogated C/EBPb and
C/EBPd degradation, confirming that KLHL9 is required for their
proteasomal processing. A more detailed time course revealed
an 2 hr half-life for these proteins following KLHL9 rescueCell 159, 402–414, October 9, 2014 ª2014 Elsevier Inc. 407
Figure 4. Rescue of KLHL9 Expression
Downregulates C/EBPb and C/EBPd Protein
Abundance, as well as Expression of
Mesenchymal Marker Genes
(A) KHLH9, C/EBPb, C/EBPd, and STAT3 protein
levels in two isolated, doxycycline-inducible
clones 48 hr after KHLH9 rescue. b-actin was used
as housekeeping control gene. See Figure S5 for
additional blots.
(B) Densitometric quantification of the bands
shows relative abundance of target proteins,
including C/EBPb/d, AURKB, and STAT3. For
each protein, values are normalized internally
to BACT and then normalized again to the
control.
(C) GSEA analysis of ARACNe-inferred targets of
C/EBPb and C/EBPd in genes differentially ex-
pressed following rescue of KLHL9 expression in
SF210. The maximum value of the enrichment
score (ES, y axis) is used to quantify relative
enrichment. A normalized enrichment score (NES)
is then calculated to allow assessing the enrich-
ment p value (Subramanian et al., 2005). The p
value and NES shown by this graph represent
the enrichment of the union of ARACNe-inferred
targets of C/EBPb and C/EBPd that are also in the
mesenchymal signature gene set (Phillips et al.,
2006). Hashes in the three boxes below the plot
indicate the rank of the ARACNe-inferred tar-
gets of these MRs and of other mesenchymal
marker genes. Canonical mesenchymal markers
are shown for reference. No significant changes in
C/EBPb and C/EBPd mRNA levels were observed
(inset).(Figure S6), compared to KLHL9/ controls where they were
stable beyond 4 hr.
KLHL9 Mediates Polyubiquitylation of C/EBPb and C/
EBPd Isoforms
To determine whether proteasomal degradation of C/EBPs de-
pends on KLHL9-mediated interaction with the CUL3 E3 ligase
complex, we collected cell lysates following rescue of KLHL9
expression and MG-132 treatment to test for ubiquitylated spe-
cies. Indeed, C/EBPb and C/EBPd polyubiquitylated isoforms
increased significantly following KLHL9 rescue, compared to
controls (Figure 5C). Reciprocal assays confirmed this result
(Figure S6).
Finally, to confirm that KLHL9-mediated C/EBP regulation
depends on a functional KLHL9-CUL3 E3 ligase complex, we
cloned amutant KLHL9 isoform with a 70 aa deletion of its N-ter-
minal BTB domain. This domain is required for ligase/target
complex recruitment to the cullin scaffold, which mediates ubiq-
uitin transfer to the target substrate (Xu et al., 2003). Expression
of mutant KLHL9 abrogated polyubiquitylation of both C/EBP
proteins in SF210 cells (Figure 5D), resulting in half-lives compa-
rable to control KLHL9/ cells.
KLHL9 Expression Delays Exit from S Phase in Glioma
Cells
To study the functional consequences of KLHL9 deletion, we
performed stable infection with KLHL9 or control expression408 Cell 159, 402–414, October 9, 2014 ª2014 Elsevier Inc.constructs in SF210 and SF763 cells, for cell-cycle analysis.
As previously reported (Rutka et al., 1987), both cell lines
were polyploid and aneuploid, with the majority of the cells
found as tetraploid (Figure S7). Rescue of KLHL9 expression
resulted in decreased growth rates in both cell lines, with
a more pronounced effect in SF210 (Figures 6A and S7).
C/EBPd protein levels decreased in both cell lines after
KHLH9 infection, and C/EBPb isoform levels decreased in
the SF210 line (Figure 6B).
Cells were then synchronized by serum-free starvation for
48 hr, released in regular media, and analyzed at selected time
points with BrdU. We observed a constant increase in cell
number in S phase in KHLH9-expressing SF210 cells relative
to controls (Figure 6C). BrdU labeling revealed active S phase
at both 4 hr and 8 hr in KLHL9-expressing SF210 cells,
compared to only 4 hr in control cells (Figure 6D). SF763 cells
also showed delayed entry into S phase (at 4 hr compared
with 2 hr in the control) and exited from S phase only by 8 hr.
However, whereas control cells re-entered S phase by 8 hr,
KHLH9-expressing cells did not, suggesting overall slowing of
cell-cycle progression, consistent with observed growth curves
(Figures 6A and S7). Finally, western blot analysis of synchro-
nized KLHL9-expressing cells also showed different kinetics
for C/EBP isoforms, variable levels of AURKB, and higher levels
of cyclin A and p21 protein expression. Taken together, our data
suggest that rescue ofKLHL9 expression delays the cell cycle by
imposing a late S/G2 checkpoint.
Figure 5. Rescue of KLHL9 Expression In-
duces Ubiquitylation and Proteasomally
Mediated Degradation of C/EBPb and
C/EBPd
Abbreviations: CH = cycloheximide; MG132 =
proteasome inhibitor.
(A)Coimmunoprecipitationassays forKLHL9andC/
EBP proteins suggest direct physical interaction.
(B) Treating SF210 cells with cycloheximide inhibits
protein translation, thus allowing assessment of
C/EBPb, C/EBPd protein-species turnover. The
decrease in C/EBP protein half-life, following
ectopic KLHL9 expression, is rescued by treatment
with proteasome inhibitor MG-132.
(C) Immunoprecipitation of C/EBPb and C/EBPd
proteins in thepresenceofMG-132 andsubsequent
analysis of ubiquitylated species by western blot.
(D) A mutant KLHL9 protein isoform that cannot
interact with the Cullin ligase was engineered by
deleting the KLHL9 BTB domain, as indicated in
the schematic. IP assays for ubiquitylated C/EBP
specieswere repeated following ectopic expression
of mutant KLHL9.
A full time course is available in Figure S6.KLHL9 Expression in KLHL9/ Patient-Derived GBM
Tumors Reduces Growth in Orthotopic Xenografts
To test whether the in vitro effects of KLHL9 rescue were recapit-
ulated in vivo, we identified a patient-derived xenograft (PDX)
model of KLHL9/ GBM (HF2354), classified as a MES-GBM
tumor by RNA-seq profile analysis. The overall workflow of this
experiment is outlined in Figure 7A. The PDX model originated
from a primary GBM tumor sample that was serially passaged in
mice. We exogenously rescued expression of KLHL9 in HF2354
via stable infection with pLOC-KLHL9 or pLOC-RFP vectors.
Ninety-six hours after lentivirus infection, cells were orthotopically
implanted in two7-mousecohorts.All 14micewereobserveddaily
and euthanized simultaneously at the first sign of distress (per
IACUC protocol). Their brains were formalin fixed, breadloaffed,
and paraffin embedded for histological assessment and IHC.
Face cuts from the blocks were H&E stained for tumor identi-
fication and scored by a board-certified pathologist, from
0 (no tumor cells present in any sections) to 3 (major portion of
hemisphere occupied by tumor). Rescue of KLHL9 expression
in HF2354 cells significantly impaired tumor growth compared
to RFP-expressing controls (Figure 7B), resulting in significant
reduction in overall tumor mass (p = 0.04). The presence of
some tumor cells was reported even in the absence of an ex-
panding mass. As such, these values and associated p values
constitute an overly cautious interpretation of the assay.
These experiments show that in vitro cell-cycle-dependent
reduction in proliferative potential, induced by ectopic KLHL9
expression in human cell cultures, is recapitulated in vivo and
induces retardation in tumor growth.Cell 159, 402–41Unbiased Inference of Driver
Alterations in BRCA and AD
To test whether DIGGIT could be general-
ized to study different disease models and
germline variants, we performed full anal-ysis (steps 1–5) of sample-matched CNV/expression data from
the TCGA breast cancer (BRCA) cohort (Cancer Genome Atlas
Network, 2012) and of sample-matched SNP/expression data
from a recent integrative study of AD (Zhang et al., 2013).
BRCA is a well-studied cancer with many established onco-
genic drivers that have been functionally or mechanistically vali-
dated. We thus first performed a literature search to identify a
repertoire of validated CNV alterations linked to BRCA tumori-
genesis. The analysis revealed a set of 25 alterations, which
are reported in Table S4, together with appropriate references.
We then performed DIGGIT and GWAS analyses using TCGA
data, naive to these publications.
To identify candidate MR genes for BRCA, we first generated
tumorigenic signatures for each tumor sample by differential
expression analysis against the set of TCGA normal breast
tissues. We then analyzed each signature using the single-sam-
pleMARINa algorithm, ssMARINa (see Experimental Procedures
and Aytes et al., 2014), to select the 10 most frequently inferred
MRs. This effectively avoids bias from BRCA subtype stratifica-
tion, while still supporting identification of subtype-specificMRs.
We chose the top 10 MRs because in previous studies, 50% to
70% of top MRs were experimentally validated. Using more
MRs would thus decrease the specificity of MINDy and aQTL
analyses without improving sensitivity (the optimal number of
MRs for the analysis may need to be selected on a case-by-
case basis).
Following candidate F-CNVG analysis, integration of MINDy
and aQTL results yielded 122 statistically significant F-CNVGs
(FDR % 0.05), of which 35 were selected by conditional4, October 9, 2014 ª2014 Elsevier Inc. 409
Figure 6. Ectopic KHLH9 Expression Decreases Cellular Proliferation by Imposing a Late S/G2 Checkpoint in Human GBM Cells
(A) Growth curves of SF210 cells after lentiviral-mediated expression of KLHL9 or RFP as a control; results are representative of three independent experiments.
(B) Western blot analysis of asynchronous SF210 and SF763 cells after reintroduction of KLHL9, showing downregulation of C/EBP-d and to a lesser extent
C/EBP-b. Both uninfected cells and RFP-infected cells are shown; b-actin serves as loading control.
(C) Cell-cycle profiles of KLHL9 and RFP-infected control SF763 cells synchronized by serum-free culture and then released into normal media for the indicated
times.
(D) BrdU incorporation by KLHL9 and RFP-infected control SF763 cells synchronized as in (C). For each time point, BrdU labeling was performed as a 1 hr pulse
preceding cell harvest.
Additional data in Figure S7.association analysis. Of these, 19 (76%) could be matched in the
25-gene literature compiled list (Table S4); yet only 5 of them
were statistically significant by GWAS, whereas the remaining
14 were missed (FDR =1). Finally, six literature-derived events
were missed by DIGGIT: two could not be identified as MINDy
modulators of top 10 MARINa-inferred MRs, whereas four
were not statistically significant by aQTL analysis. A summary
of this analysis is provided in Table S4.
Analysis of an AD cohort, using patient-matched, brain gene
expression and genotypic profiles from affected and nonaf-
fected individuals, identified TYROBP as a candidate germline
determinant of the disease (Zhang et al., 2013). We downloaded
the publicly available data used in these analyses and performed
unbiased DIGGIT analysis, naive to the published results.
Because this analysis was based on SNPs, we modified step 2
to identify candidate F-SNPs by selecting those within 1 kb
of a corresponding gene’s coding region (see Extended410 Cell 159, 402–414, October 9, 2014 ª2014 Elsevier Inc.Experimental Procedures). Similar to BRCA analysis, we used
ssMARINa to identify the 10 most frequent MRs (see Experi-
mental Procedures). DIGGIT identified 112 F-SNPs, with 63
passing MINDy/aQTL integration and 13 also significant by con-
ditional association analysis. Among these, TYROBPwas ranked
1st (p = 4.2 3 1047), achieving higher significance than even
APOE, ranked 9th (p = 2.0 3 1021) (see Tables S5 and S6). An
additional candidate SNP identified in the original publication
(FCER1G) was ranked 8th (p = 9.1 3 1022) by our analysis.
DISCUSSION
Following 10 years of GWASs, elucidating the repertoire of
causal genetic determinants of most complex diseases has
proven more challenging than expected. Due to the large num-
ber of candidate loci, it is difficult to achieve the statistical po-
wer to detect all but the most highly penetrant and frequent
Figure 7. Ectopic KLHL9 Expression, in
Patient-Derived KLHL9/ GBM Tumors,
Reduces Growth in Orthotopic Xenografts
(A) Workflow of the PDX mouse model. Primary
tumor samples are retrieved from human patients
and explanted into mice for propagation instead of
traditional in vitro cell culture.
(B) Brain sections of mice given orthotopic in-
jections of KLHL9-rescued or RFP control human-
derived GBM cells (HF2354) reveal a significant
decrease in tumor number and size. Clinical
scoring of tumor size from a certified pathologist
indicates a statistically significant difference in
tumor growth rates (p = 0.04). H&E staining of face
sections reveals significantly reduced surface area
of tumor masses and is also provided.events. Furthermore, when relevant genetic determinants
emerge from these analyses, their mechanistic validation may
lag by decades. At the other end of the spectrum, candidate-
gene-based biochemical studies can provide insight into causal
regulatory mechanisms but do not effectively scale up to
genome-wide coverage, due to their time consuming and labo-
rious nature.
To address both challenges, we introduced DIGGIT, an algo-
rithm for the network-based elucidation of genetic determinants
of human disease, resulting in dramatic reduction of testable
hypotheses and availability of regulatory clues to guide mecha-
nistic validation. The key algorithm’s requirement is a large
repertoire of sample-matched gene expression and genetic
variant profiles. As such, it is directly applicable to many tumor
contexts and to an increasing number of germline diseases
and traits.
The specific genetic etiology of most diseases is highly hetero-
geneous and thus largely patient specific. Yet, we hypothesize
that diverse alteration patterns induce common aberrant
signals, converging on regulatory modules and associated MR
proteins that represent key regulatory bottlenecks, whose
dysregulation is both necessary and sufficient for disease initia-
tion/progression. The existence and role of MR proteins and
modules representing regulatory bottlenecks has been demon-
strated in a variety of tumor contexts (Aytes et al., 2014; Carro
et al., 2010; Chudnovsky et al., 2014; Compagno et al., 2009;Cell 159, 402–41De Keersmaecker et al., 2010; Della
Gatta et al., 2012; Lefebvre et al., 2010;
Lim et al., 2009; Piovan et al., 2013;
Zhao et al., 2009). Once identified, how-
ever, it is reasonable to assume that driver
genetic events must be harbored either by
theseMRs or by their upstream pathways.
The mesenchymal subtype of GBM,
representative of poor prognosis, pro-
vides an ideal context to test this rationale,
as its established genetic determinants
account for < 25%of the patients. Starting
from previously established MES-GBM
MRs (Carro et al., 2010), DIGGIT identified
C/EBPd amplifications and KLHL9 dele-tions as novel, causal determinants of aberrant MES-GBM MR
activity. We confirmed KLHL9 deletions in an independent
cohort and showed that this protein is necessary for Cul3-
ligase-mediated ubiquitylation and proteasomal degradation of
establishedMES-GBMMRs, C/EBPb and C/EBPd. Interestingly,
only one MES-MRs (C/EBPd) harbored driver alterations, sug-
gesting that typical MARINa-inferred MRs represent non-onco-
gene dependencies of cancer cells (Luo et al., 2009; Schreiber
et al., 2010), as also confirmed by additional studies (Aytes
et al., 2014; Carro et al., 2010; Chudnovsky et al., 2014; Com-
pagno et al., 2009; Lim et al., 2009; Piovan et al., 2013; Zhao
et al., 2009).
Initial evidence supporting the existence of regulatory bottle-
necks that integrate aberrant signals from multiple mutations
to implement a common disease phenotype first emerged in
earlier studies of Nf-kB as non-oncogene dependency in diffuse
large B cell lymphoma. Mutations in several BCR pathway genes
(e.g., TNFAIP3, CARD11, MYD88, etc.) elicited dependency on
Nf-kB, even though its subunits were not mutated (Compagno
et al., 2009; Davis et al., 2001). More recent examples of
MARINa-inferred non-oncogene dependencies include AKT1
as an MR of glucocorticoid resistance in T-ALL, downstream of
PTEN and PI3K mutations (Piovan et al., 2013), and FOXM1
and CENPF as synergistic MRs of aggressive prostate cancer
(Aytes et al., 2014), downstream of several genetic and epige-
netic alterations, currently undergoing experimental validation.4, October 9, 2014 ª2014 Elsevier Inc. 411
Thus, although regulatory bottlenecks may not represent a uni-
versal mechanism in cancer, when present, they can substan-
tially contribute to identification of driver alterations. Additionally,
canalization of aberrant signals from genetic events in upstream
pathways is not necessarily restricted to cancer. Indeed, we
showed that DIGGIT could be successfully applied to elucidating
genetic determinants of AD risk. Specifically, to show that the
algorithm can be applied to multiple disease contexts driven
by either somatic alterations or germline variants, we showed
that DIGGIT could successfully identify 19 established CNV
drivers of breast ductal adenocarcinoma and 3 established risk
alleles for AD, as well as several novel, high-probability alter-
ations and variants that deserve further experimental testing.
Critically, the vastmajority of these events could not be identified
by GWAS.
The ability to interrogate de novo reverse-engineered net-
works upstream of established functional regulators has several
implications. First, it forgoes the need to evaluate each locus in
the genome as an equivalent candidate driver, which incurs a
statistical cost that greatly reduces the power of current GWAS
methods. This is especially critical when multiple low-pene-
trance or low-frequency events converge on the same functional
regulator, or when genetic alterations may have epistatic/syner-
gistic effects. For instance, the dramatic reduction in candidate
driver alterations afforded by DIGGIT allowed efficient use of
conditional association methods to further distinguish driver
from passenger alterations and to discover candidate codepen-
dent events, such as independent events in C/EBPd and NF1.
Second, discovery of genetic drivers upstream of MRs previ-
ously established as therapeutic targets is likely to provide valu-
able genetic biomarkers for targeted therapeutic intervention.
Finally, MR-based discovery of genetic alterations may help
identify alterations that are either not focal (e.g., in large ampli-
cons) or masked by close proximity to well-established onco-
genes and tumor suppressors that would likely prevent their
identification, as was the case for the homozygous KLHL9
deletions.
With respect to the specific finding in GBM, our results impli-
cate KLHL9 deletions as mechanistic MES-GBM drivers, by
abrogating ubiquitin-dependent proteasomal degradation of
two MR proteins, C/EBPb and C/EBPd, and by increasing
levels of phosphorylated STAT3. At least two other genes
coding for E3 ubiquitin ligases were reported to undergo
loss-of-function genetic alterations in GBM. The first one codes
for FBW7, an F box protein of the SCF complex that is mutated
in several forms of human cancer including GBM (Thompson
et al., 2007). FBW7 mutations stabilize the oncoprotein sub-
strates CCNE1, MYC, and NOTCH1 (Nakayama and Na-
kayama, 2006). The second one, encoding an E3 ligase that
is deleted in GBM, is HUWE1, a Hect-domain ubiquitin ligase
that triggers initiation of differentiation and loss of self-renewal
in the developing brain by targeting the MYCN oncoprotein
for ubiquitin-mediated degradation (Zhao et al., 2009). Our
findings indicate that loss-of-function events targeting E3 ubiq-
uitin ligases such as KLHL9 in human cancer not only promote
aberrant stabilization of classical oncoproteins but also can
trigger accumulation of key TFs responsible for tumor lineage
reprogramming.412 Cell 159, 402–414, October 9, 2014 ª2014 Elsevier Inc.Finally, the ability to identify both cancer bottlenecks and
their candidate upstream functional regulators depends critically
on the availability of sample-matched gene-expression/genetic-
variant profiles and accurate and comprehensive repertoires
of cell-context-specific molecular interactions (interactomes).
Although the assembly of integrated transcriptional, posttran-
scriptional, and posttranslational interactomes is still in its
infancy, the genome-wide integration of experimental and
computational approaches is already starting to provide biolog-
ically relevant models. This further suggests that network-based
methodologies may be increasingly valuable entries in the toolkit
for the identification and mechanistic elucidation of genetic
determinants of physiological and disease-related phenotypes,
using ever-increasing volumes of genomic data.
EXPERIMENTAL PROCEDURES
This section includes short summaries of the experimental and computational
methods used in this manuscript. Full method description and utilization
details are provided in the Extended Experimental Procedures, including pa-
rameters and input/output data for the use of published algorithms (ARACNe,
MINDy, ssMARINA). A software package (DIGGIT), with all relevant functions
discussed in this section, as well as a ‘‘sweave’’ file to reproduce the results
of the analysis are available at the lab-software website (http://wiki.c2b2.
columbia.edu/califanolab/index.php/Software).
Inference of F-CNVGs
Each F-CNVG (FCi) is assessed based on the statistical significance of the MI,
IF[CNVi;mRNAi], where mRNAi represents its expression and CNVi its copy
number across a sample-matched cohort. Thresholds for CNV calling are
assessed from the distribution in control samples. The DIGGIT package in-
cludes the .fCNV function to measure MI using a fixed-bandwidth Gaussian
Kernel estimator and false discovery rate (FDR), by gene shuffling, to assess
statistical significance. Low-frequency alterations, occurring in fewer than
seven samples (thus not appropriate for MI analysis), are tested for differential
expression in altered versus WT samples via t test or Z test.
MINDy and aQTL Analyses
MINDy
Use of the algorithm to generate a list of candidate MR modulators is fully dis-
cussed in the Extended Experimental Procedures and in Wang et al. (2009).
aQTL
For each F-CNVG (FCi), the .aQTL function is used to compute MIaQTL[CNVi;
MRj], i.e., the MI between its copy number (CNVi) and the ssMARINa-inferred
activity of each MES-MR protein (MRj) to assess the aQTL p value. MES-GBM
MRs included the following: C/EBPb, C/EBPd, STAT3, FOSL2, BHLHB2, and
RUNX1 (see Carro et al., 2010). The aQTL and MINDy p values are integrated
by Fisher’s method, implemented in the .integrate function.
F-CNVG Clustering and Conditional Association
Clustering
The .cluster function is used to test each F-CNVG pair for same-sample co-
occurrence by pairwise FET; amplifications and deletions are tested sepa-
rately. Clusters include all gene pairs with statistically significant association.
Conditional Association
For each F-CNVG pair (FCi,FCi) in a cluster, the .ca function is used to test
whether FCi is no longer significantly associated with the target phenotype
(i.e., MES-GBM) when samples with FCj alterations are removed. Each candi-
date FCi is given a score, SCA, by counting the number of F-CNVGs in the clus-
ter whose association with the phenotype is abrogated when conditioning on
FCi, minus the number of F-CNVGs for which FCi’s association is abrogated.
For example, KLHL9 abrogated MES-GBM association of 14 out of 14 other
F-CNVGs in cluster 2. Conversely, KLHL9’s association was never abrogated
by these F-CNVGs (SCA = 14  0 = 14).
Classification of TCGA GBM Tumors
We classified all TCGA GBM tumor samples into MES, PN, or PRO, per the
original definitions (Phillips et al., 2006). The three genes with the highest
variance across the cohort in this work were used for classification:
SERPINE1, CHI3L1, TIMP1 (MES); BCAN, OLIG2, KLRC3 (PN); and
HMMR, TOP2A, PCNA (PRO). TCGA samples were classified based on
these markers, by unsupervised k-means clustering (available in the Bio-
conductor R package).
Orthotopic Xenograft Mouse Models
The orthotopic intracranial xenograft model was conducted under a protocol
approved by the Translational Drug Development (TD2) Institutional Animal
Care and Use Committee. Female nude mice (age 4–5 weeks) were random-
ized into groups of seven that received either HF2354 cells transduced with
a control vector or a vector expressing KLHL9. At 96 hr following lentivirus-
mediated transduction, cells were injected into the right basal ganglia using
a small animal stereotaxic frame (TSE Systems). Mice were weighed daily
and observed for the onset of neurologic symptoms or distress. When the first
mouse from either study cohort was euthanized due to neurological symptoms
or distress, all other mice in both cohorts were euthanized, and formalin-
perfused brains were harvested and embedded in paraffin. Immunohisto-
chemistry and H&E staining were performed, and a board-certified pathologist
scored the sections: 0, no tumor; 1, small tumor or presence of dispersed
tumor cells in any tissue section; 2, medium-size tumor; 3, large tumor occu-
pying major areas of the hemisphere.
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